Orexigen Therapeutics (NASDAQ: [[ticker:OREX]]), the San Diego-based developer of obesity drugs, said today it has added four new executives to its management team. Dawn Viveash is the new head of global regulatory affairs; Suzanne McDonald will be responsible for managed markets and government affairs; Preston Klassen will be the head of the global Contrave program; and Whedy Wang is the new head of global biomedical information. CEO Mike Narachi explained his plan for re-inventing the company, and some of the other new managers he brought in earlier this year, in a feature back in September.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
